GENE SOLUTIONS WELCOMES KENG HSU AS NEW CHIEF FINANCIAL OFFICER 

Singapore, 1st Jul 2025 – Gene Solutions, a leading biotech innovator in precision medicine and genetic testing, is pleased to announce the appointment of Keng Hsu as our new Chief Financial Officer (CFO). This strategic addition reflects the company’s continued focus on scaling its operations globally and strengthening its financial leadership amid rapid growth across Asia-Pacific (APAC) and beyond. 

Singapore, 1st Jul 2025 – Gene Solutions, a leading biotech innovator in precision medicine and genetic testing, is pleased to announce the appointment of Keng Hsu as our new Chief Financial Officer (CFO). This strategic addition reflects the company's continued focus on scaling its operations globally and strengthening its financial leadership amid rapid growth across Asia-Pacific (APAC) and beyond.  

Keng Hsu brings over 20 years of professional experience across finance, business operations, fundraising, M&A, and executive leadership. A qualified CPA and seasoned executive, Keng has held senior roles at prominent firms including Esco Lifesciences (Group CFO) and Yourgene Health (Chief Operating Officer – Asia, and Chief Commercial Officer – APAC), where he played a pivotal role in IPO preparation, investor engagement, and business expansion initiatives. 

Educated at prestigious institutions including INSEAD, Tsinghua University, and the University of Melbourne, Keng holds an Executive MBA and a strong academic background in finance, accounting, and the skills to speak various languages. His international experience across Singapore, Taiwan, India, the UK, and Australia complements Gene Solutions’ multicultural team and diverse market presence. 

As part of this transition, Nguyen Ngoc Hoa, who has served as Gene Solutions’ Chief Financial Officer since its early stages, will take on a new role and continue contributing as our Senior Advisor. Hoa has been instrumental in building the company’s financial infrastructure and supporting its growth across Southeast Asia. His continued involvement will ensure a smooth transition and provide strategic counsel as Gene Solutions expands into new markets and investment opportunities. 

“I’m honored to join Gene Solutions at such a transformative time in its journey,” said Keng Hsu. “What excites me most is the company’s bold vision to democratize access to precision medicine through innovation in genomics and artificial intelligence. I look forward to working alongside a passionate team to strengthen financial strategy, support cross-border partnerships, and scale our impact across APAC and beyond.” 

Dr. Nguyen Huu Nguyen, Co-founder & Deputy CEO at Gene Solutions, added, “Keng’s track record in financial strategy, fundraising, and operations aligns perfectly with our mission and strategy. His experience and leadership will be key as we scale our impact across global markets.” 

At Gene Solutions, we’re energized by the strategic direction Keng Hsu will bring to our future growth and global expansion.

Stay connected with us on our website and social media to discover more about the people and science driving our mission forward. 

LATEST News

ESMO 2026 Gene Solutions Global Industry Satellite Symposium AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

MADRID, Nov. 18, 2026 — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies span ning cancer screening, precision oncology, and functional applications.     ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a

Read More
Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation.  The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology.  Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong,

Read More
New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More